Shattuck Labs

STTK

Market cap $247M

3.86 USD

-0.05

1.28%

At close Updated Feb 13, 4:00 PM EST

Pre-market

After hours

3.71

-0.15

3.89%

1 day

-1.28%

5 days

1.58%

1 month

-14.41%

3 months

109.78%

6 months

376.13%

Year to date

4.04%

1 year

208.8%

5 years

-91.27%

10 years

-80.05%

About: Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Employees: 44

Healthcare Biotechnology